Arrowstreet Capital’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$30.4M Buy
1,280,701
+803,560
+168% +$20M 0.01% 689
2026
Q2
$11.6M Buy
+477,141
New +$8.13M 0.01% 1030
2024
Q3
– Sell
-60,084
Closed -$1.25M – 1826
2024
Q2
$1.25M Sell
60,084
-127,659
-68% -$1.99M ﹤0.01% 1174
2024
Q1
$2.76M Sell
187,743
-7,393
-4% -$79.5K ﹤0.01% 1057
2023
Q4
$2.01M Buy
+195,136
New +$1.34M ﹤0.01% 966

Other funds holding NRIX

Arrowstreet Capital's NRIX Position: Q3 2026 in Review

Arrowstreet Capital increased its Nurix Therapeutics (NRIX) stake by 168% in Q3 2026, buying an estimated $20M and bringing the position to 1,280,701 shares worth $30.4M. The position accounts for 0.01% of the portfolio, ranked #689.

Arrowstreet Capital first reported a position in NRIX in Q4 2023 and has held it in 5 quarters since. 231 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Arrowstreet Capital held 1,280,701 shares of Nurix Therapeutics worth $30.4M as of Q3 2026.
  • Arrowstreet Capital bought 803,560 Nurix Therapeutics shares in Q3 2026, an estimated $20M.
  • Nurix Therapeutics made up 0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #689 holding.
  • Arrowstreet Capital first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • 231 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.